NASDAQ:INM InMed Pharmaceuticals Q2 2026 Earnings Report $1.39 -0.01 (-0.79%) As of 02:24 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast InMed Pharmaceuticals EPS ResultsActual EPS-$0.51Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInMed Pharmaceuticals Revenue ResultsActual Revenue$0.82 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInMed Pharmaceuticals Announcement DetailsQuarterQ2 2026Date2/12/2026TimeAfter Market ClosesConference Call DateWednesday, February 11, 2026Conference Call Time7:00AM ETUpcoming EarningsInMed Pharmaceuticals' Q1 2027 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) InMed Pharmaceuticals Earnings HeadlinesInMed Pharmaceuticals: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity ComplianceSeptember 19, 2026 | finanznachrichten.deInMed Pharmaceuticals (INM) Expected to Announce Quarterly Earnings on WednesdaySeptember 16, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 25 at 1:00 AM | InvestorPlace (Ad)InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine PipelineJuly 22, 2026 | benzinga.comMentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention PipelineJuly 22, 2026 | prnewswire.comInMed Pharmaceuticals Inc.June 29, 2026 | barrons.comSee More InMed Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InMed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMed Pharmaceuticals and other key companies, straight to your email. Email Address About InMed PharmaceuticalsInMed Pharmaceuticals (NASDAQ:INM) is a biopharmaceutical company focused on the discovery and development of pharmaceutical products based on rare cannabinoids. The company combines cannabinoid science with drug-development expertise to investigate potential treatments for diseases with significant unmet medical needs. Its research pipeline has included INM-901, an investigational rare-cannabinoid therapy being developed for Alzheimer’s disease, as well as earlier programs targeting conditions such as epidermolysis bullosa and glaucoma. InMed also develops proprietary cannabinoid formulations and drug-delivery approaches intended to improve the therapeutic potential of cannabinoid-based medicines. In 2022, InMed acquired BayMedica, a producer of rare cannabinoids, expanding its capabilities in cannabinoid development and commercialization. The company is headquartered in Vancouver, British Columbia, and serves the global pharmaceutical and biotechnology markets through its research, development and specialty cannabinoid activities. InMed is led by Chief Executive Officer Eric A. Adams.View InMed Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
